Abstract
Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Current Neuropharmacology
Title: Past, Present and Future Therapeutics for Cerebellar Ataxias
Volume: 8 Issue: 1
Author(s): D. Marmolino and M. Manto
Affiliation:
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Abstract: Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Export Options
About this article
Cite this article as:
Marmolino D. and Manto M., Past, Present and Future Therapeutics for Cerebellar Ataxias, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909476
DOI https://dx.doi.org/10.2174/157015910790909476 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spinal Muscular Atrophy: Molecular Mechanisms
Current Molecular Medicine Brain Perfusion SPECT with Brodmann Areas Analysis in Differentiating Frontotemporal Dementia Subtypes
Current Alzheimer Research Effects of Synthetic Peptides on the Inflammatory Response and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Using NMR to Develop New Allosteric and Allo-Network Drugs
Current Drug Discovery Technologies Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Current Drug Targets Structural Bioinformatics: Methods, Concepts and Applications to Blood Coagulation Proteins
Current Protein & Peptide Science MR-Based In Vivo Analysis of Joint Biomechanics and its Relevance in the Pathogenesis of Osteoarthritis
Current Rheumatology Reviews Recent Advances in Potential Therapeutic Drugs for Cognitive Impairment in Schizophrenia
Current Psychiatry Reviews Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science Mechanism of Action of Volatile Anesthetics: Involvement of Intracellular Calcium Signaling
Current Drug Targets - CNS & Neurological Disorders Repetitive Transcranial Magnetic Stimulation to Treat Substance Use Disorders and Compulsive Behavior
CNS & Neurological Disorders - Drug Targets Relative Hypermetabolism of Vermis Cerebelli in Traumatic Brain Injured Patients Studied with 18FDG PET: A Descriptor of Brain Damage and a Possible Predictor of Outcome
Current Radiopharmaceuticals Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery Molecular Linkages Between Diabetes and Alzheimer's Disease: Current Scenario and Future Prospects
CNS & Neurological Disorders - Drug Targets The Role of Redox Dysregulation in the Inflammatory Response to Acute Myocardial Ischaemia-reperfusion Injury - Adding Fuel to the Fire
Current Medicinal Chemistry A Missed Proteome in Living Organisms: A Hyppo System
Current Proteomics The Genetic Basis of Sleep Disorders
Current Pharmaceutical Design Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Preterm Infant Swallowing and Respiration Coordination During Oral Feeding: Relationship to Dysphagia and Aspiration
Current Pediatric Reviews